Comparing Buzzy Ⓡ and Pikluc Ⓡ for Pain Relief in Pediatric Intramuscular Injections: A Randomized Equivalence Trial.

Pain Manag NursApr 21, 2026 (epub)
Clinical ResearchPediatrics

Jefferson Wildes da Silva Moura, Mari Takashima, Sabrina de Souza et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized equivalence trial evaluated the effectiveness of Buzzy Ⓡ and Pikluc Ⓡ for pain relief during intramuscular injections in children aged 1-11 years. In children aged 1-3 years, all devices demonstrated equivalent pain relief, while in those aged 4-11 years, self-reported pain did not show equivalence. The study included 170 participants.

Key findings

  • In children aged 1-3 years, all device comparisons showed equivalence in pain relief.
  • For ages 4-11 years, self-reported pain did not show equivalence across devices.
  • Observer-reported assessments suggested equivalence for Pikluc Ⓡ vs. Buzzy Ⓡ 30 seconds in older children.

Why it matters

Understanding effective non-pharmacological pain relief methods is crucial for improving the experience of pediatric patients during procedures. This study provides insights into the use of two devices that can help reduce pain during intramuscular injections.

Source

Published in Pain Manag Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.